HIV/HCV Coinfection: Considerations about Treatment
- *Corresponding Author:
- Shirley Vasconcelos Komninakis
Federal University of São Paulo
R. Pedro de Toledo, n. 781
São Paulo, Brazil
E-mail: [email protected]
Received Date: April 29, 2014; Accepted Date: July 14, 2014; Published Date: July 16, 2014
Citation: de Azevedo RG, Komninakis SV (2014) HIV/HCV Coinfection: Considerations about Treatment. J Med Microb Diagn 3:148. doi: 10.4172/2161-0703.1000148
Copyright: © 2014 de Azevedo RG. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Infections are considered public health problems. The coinfection HIV/HCV is common in individuals exposed to parenteral exposure, and HVC has emerged as the leading cause of deaths among HIV-1-seropositive patients. The treatment of HIV/HCV coinfected people should be able to suppress viral replication for both viruses, with the purpose of to improve the immunological response and include liver damage. These two aspects should be associated with a high safety profile, because the toxicity of antiretroviral drugs used to treat HIV in HIV/HCV coinfected people, can lead them to death. The management of the treatment of patients is needed to monitor and, if possible, prevent complications related to adverse effects.